-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Shanghai Sunshine Pharmaceutical Procurement Network released information that in order to do a good job in the protection of intellectual property rights in the field of pharmaceutical bidding and procurement, the procurement qualification
of linagliptin tablets (specification: 5mg× 7 tablets / plate × 1 board / box) produced by Guangdong East Sunshine Pharmaceutical Co.
, Ltd.
was suspended.
Source: _msthash="320191" _msttexthash="88454847">Previously, on September 22, the Guangzhou Public Resources Exchange Center also issued an announcement, saying that in order to do a good job in the protection of intellectual property rights in the process of drug hanging online, the procurement platform of Guangzhou Pharmaceutical Group will suspend the qualification
of linagliptin tablets (5mg, 7 tablets / box) of Guangdong East Sunshine Pharmaceutical Co.
, Ltd.
Source: https://gpo.
gzggzy.
cn/
East Sunshine Medicine won the first visit in China, and won the original patent case
East Sunshine Medicine won the first visit in China, and won the original patent caseAccording to GBI
SOURCE global drug database, linagliptin (O'Downing) is a Boehringer Ingelheim self-developed innovative product, approved for marketing in China in 2013, for the treatment of adult patients with
type 2 diabetes.
These drugs can inhibit the inactivation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulin-secreting polypeptides (GIP), increase the levels of endogenous GLP-1 and GIP, promote the release of insulin by islet β cells, and inhibit the secretion of glucagon by islet α cells, thereby increasing insulin levels, lowering blood sugar, and not easily inducing hypoglycemia and weight gain
.
China is the world's largest country in diabetes, and the prevalence rate is on the rise
.
According to Frost & Sullivan, the number of people with diabetes in China increased from 118 million in 2016 to 133 million in 2020, and the prevalence of diabetes among adults was as high as 11.
9%
in 2020.
With the continuous advancement of medical reform, the vigorous development of innovative drugs, and the enhancement of patients' ability to pay, the market potential of diabetes drugs is huge, and the market size is expected to be close to 86.
2 billion yuan
by 2032.
In the face of the tens of billions of market, many domestic generic drug companies have accelerated the pace of research and development, trying to take a "piece of the pie"
.
According to GBI
SOURCE global drug database, in July 2020, East Sunshine Drug lintagliptin first imitation approved for the treatment of adult type 2 diabetes
.
Since then, generic drugs from CSPC Group, Yangtze River Pharmaceutical, Kelun Pharmaceutical and Huahai Pharmaceutical have been approved for marketing
.
It is reported that since February 2021, Dongguang Medicine, which won the first imitation of the drug, has begun to be published on the drug procurement platform of many provinces (autonomous regions and municipalities) and promised to sell linagliptin products to medical institutions in the region, which has also attracted the attention of the original research company Boehringer Ingelheim, and launched infringement lawsuits
against generic drug companies.
In July 2022, the case ended with the State Intellectual Property Office ruling that East Sunshine had infringed a Boehringer Ingelheim patent protecting a linagliptin compound, and CNIPA ordered East Sunshine to cease all infringements, including the manufacture, sale and promise to sell generic lidagliptin tablets
.
According to relevant laws and regulations, although East Sunshine may file an administrative lawsuit against the award within the prescribed time limit, the enforcement
of the administrative ruling will not be suspended during the litigation period.
.
According to GBI
SOURCE global drug database drug patent radar, a total of 5 patents of the drug registered on the CDE patent information platform, the expiration date varies from February 2022 to April 2027, the domestic Hangzhou Minsheng Pharmaceutical Industry made a class 2 and 3 patent claims
for the drug.
Source: GBI SOURCE Global Drug Database Drug Patent Radar
GBI SOURCE Drug Patent RadarThe implementation of the new Patent Law in June 2021 and the pharmaceutical patent linkage system in July 2021 have created a new legal regulatory environment
for new drug transactions.
It is foreseeable that in the future, the patent war between original research pharmaceutical companies and generic drug companies may continue to start, and the patent strategy of innovative drugs will also become one of
the important topics for relevant enterprises in the industry.
Little G will take advantage of GBI
The drug patent radar section of SOURCE Global Drug Database continuously tracks and regularly inventories drug patent claim information, helping you know yourself and others under the new patent system and improve the value return
of innovative products.
